8 резултати
OBJECTIVE
The aim of the study was to evaluate the laboratory and endometrial safety of topical testosterone versus topical estrogen for the treatment of vaginal atrophy in postmenopausal women.
METHODS
This was a randomized, placebo-controlled trial of 60 postmenopausal women aged 40 to 70 years at
The changes that occur in sex hormone levels, body composition, and lipid/lipoprotein levels during the menopause transition, together with vascular remodeling, increase the risk of cardiovascular disease (CVD) in postmenopausal women. Any treatments prescribed for concomitant conditions during
Percutaneous application of estradiol in the postmenopause is considered to be a promising alternative to oral estrogen replacement therapy. Since it avoids the first liver passage, the resulting circulatory hormone patterns seem to be more physiological and the dose can be greatly reduced. The
Ospemifene (Ophena) is a new selective oestrogen receptor modulator currently in phase III clinical development for treatment of post-menopausal vulvar and vaginal atrophy. In the present study, we examined the pharmacokinetics, toxicity, and DNA adduct forming potential of ospemifene in the liver
The focus of this review is hormone replacement therapy (HRT) with continuous administration of micronized, oral 17beta-estradiol 1 mg/day (herein referred to as continuous estradiol) plus micronized, oral norgestimate 90 microg/day administered for 3 days then withdrawn for 3 days in a 6-day
The focus of this review is hormone replacement therapy (HRT) with continuous administration of micronised, oral 17beta-estradiol 1 mg/day (herein referred to as continuous estradiol) plus micronised, oral norgestimate 90 microg/day administered for 3 days then withdrawn for 3 days in a 6-day
The effects of treating climacteric complaints in post-menopausal women were studied in an open trial in which Org OD 14, a placebo and no treatment were compared. In addition to the symptomatic effects, clinical and laboratory parameters were also studied. One hundred and twenty-four women who had
OBJECTIVE
This study was conducted to investigate the efficacy of black cohosh (Cimicifuga racemosa) and St. John's wort (Hypericum perforatum) in women with climacteric symptoms, and to assess their effects on vaginal atrophy, hormone levels, and lipid profiles.
METHODS
In this double-blind